Laila S. Tabatabai, MD is a board-certified endocrinologist with expertise in osteoporosis, fragility fractures and metabolic bone diseases.  Her postdoctoral training included a fellowship in endocrinology at Johns Hopkins Hospital, internship and residency in internal medicine at the University of Maryland Medical Center in Baltimore.  She received her medical degree, with distinction in research, at Albany Medical College in New York. 

Dr. Tabatabai is an Associate Professor of Clinical Medicine with the Houston Methodist Academic Institute and Weill Cornell Medical College.  She is a member of the Board of the Bone Health and Osteoporosis Foundation (BHOF), which is dedicated to patient advocacy and educational efforts for those affected by osteoporosis and bone diseases.  Dr. Tabatabai has presented at national meetings including the American Association of Clinical Endocrinologists (AACE), Endocrine Society, American Society of Bone and Mineral Research and the Endocrine Nurses Society Symposium. 

Dr. Tabatabai has been the recipient of numerous research grants in the area of osteoporosis and anabolic medications.  She has authored peer-reviewed publications appearing in the Journal of Clinical Endocrinology and Metabolism, Endocrine Practice and other journals.  She is considered an expert in the field of anabolic agents for treatment of fragility fractures in high-risk osteoporosis patients. 

Dr. Tabatabai is the Principle Investigator for the Disease Monitoring Program for burosumab, an anti-FGF23 monoclonal antibody which corrects phosphate homeostasis in individuals with X-linked hypophosphatemic rickets.  She has chaired the Endocrine Society’s CME and MOC-certified educational program on hypophosphatemia.